Changes in cognition and amyloid-β processing with long term cholesterol reduction using atorvastatin in aged dogs

Journal of Alzheimer's Disease

Volumn 22, Issue 1, 2010, Pages 135-150

  Murphy, M Paul ^a,b   Morales, Jacqueline ^c   Beckett, Tina L ^a   Astarita, Giuseppe ^c   Piomelli, Daniele ^c   Weidner, Adam ^a,b   Studzinski, Christa M ^a   Dowling, Amy L S ^a   Wang, Xiaohong ^a   Levine III, Harry ^a,b   Kryscio, Richard J ^a,b   Lin, Yushun ^a,b   Barrett, Edward ^d   Head, Elizabeth ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Amyloid protein precursor (A PP); canine; cholesterol; dog; LRP 1; statin; secretase (BACE1)

Indexed keywords

AMYLOID BETA PROTEIN; ATORVASTATIN; BETA SECRETASE 1; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; TRIACYLGLYCEROL;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DYSFUNCTION; CEREBROSPINAL FLUID; CHOLESTEROL BLOOD LEVEL; COGNITION; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; LEARNING; MEMORY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; SPATIAL MEMORY; TEMPORAL CORTEX;

EID: 78650636473     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100639     Document Type: Article

References (97)

1. Mirra SS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging 18, S91-S94.
2. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
3. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57, 1439-1443.
4. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59, 223-227.
5. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP (2002) The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57, M414-M418.
6. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M (2002) Use oflipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc 50, 1852-1856.
7. Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzou-rio C, Amouyel P, Alperovitch A (2005) APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 64, 1531-1538.
8. Zamrini E, McGwin G, Roseman JM (2004) Association between statin use and Alzheimer's disease. Neuroepidemiology 23, 94-98.
9. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence ofdementia and Parkinson's disease. BMC Med 5, 20.
10. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, van Belle G, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB (2004) Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63, 1624-1628.
11. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH (2005) Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62, 1047-1051.
12. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62, 217-224.
13. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Bretel-er MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80, 13-17.
14. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956-964.
15. Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ, Stott DJ, Shepherd J, Bollen EL, Blauw GJ, Jukema JW, Wes-tendorp RG Pravastatin and cognitive function in the elderly. Results ofthe PROSPER study. J Neurol 257, 85-90.
16. McGuinness B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev, CD003160.
17. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22.
18. Rockwood K (2006) Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand Suppl 185, 71-77.
19. Sparks L (2009) Statins and cognitive function. J Neurol Neu-rosurg Psychiatry 80, 1-2.
20. Simons M, Keller P, Strooper BD, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95, 6460-6464.
21. Hartmann T (2001) Cholesterol, A beta and Alzheimer's disease. Trends Neurosci 24, S45-S48.
22. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, Bergmann Kv, Henner-ici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98,5856-5861.
23. Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20, 154-159.
24. Selkoe DJ (1996) Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 271, 18295-18298.
25. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321331.
26. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13, 455-459.
27. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8, 890-899.
28. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, Duff K, Pappolla M, Refolo LM (2002) Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 19, 155-161.
29. Alberts AW (1990) Lovastatin and simvastatin-inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology 77, 14-21.
30. Fears R, Richards DH, Ferres H (1980) The effect of com-pactin, a potent inhibitor of 3-hydroxy-3-methylgutaryl co-enzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 35, 439449.
31. Todd PA, Goa KL (1990) Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholes-terolaemia. Drugs 40, 583-607.
32. Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, Andersson U, von Eckardstein A, Bjorkhem I, Lutjohann D (2006) Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 316, 1146-1152.
33. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Ma-jka JA, Stubbs RJ, Bokelman DL (1989) Animal safety and toxicology ofsimvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 87, 28S-38S.
34. Wisniewski HM, Wegiel J, Morys J, Bancher C, Soltysiak Z and Kim KS (1990) Aged dogs: an animal model to study beta-protein amyloidogenesis. In Alzheimer's disease. Epidemiology, Neuropathology, Neurochemistry and Clinics, K. Maurer PR, and H. Beckman, ed. Springer-Verlag, New York, pp. 151-167.
35. Cummings BJ, Su JH, Cotman CW, White R and Russell MJ (1993) Beta-amyloid accumulation in aged canine brain: a model of plaque formation in Alzheimer's disease. Neurobiol Aging 14, 547-560.
36. Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW (2000) Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging 21, 89-96.
37. Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP (1991) Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res 10, 299-305.
38. Selkoe DJ, Bell DS, Podlisny MB, Price DL and Cork LC (1987) Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 235, 873-877.
39. Milgram NW, Head E, Weiner E, Thomas E (1994) Cognitive functions and aging in the dog: Acquisition of nonspatial visual tasks. Behav Neurosci 108, 57-68.
40. Head E, Milgram N.W. and Cotman C.W. (2001) Neurobi-ological Models of Aging in the Dog and Other Vertebrate Species In Functional Neurobiology of Aging, In. P. Hof and Mobbs C, ed. Academic Press, San Diego, pp. 457-468.
41. Studzinski CM, Christie LA, Araujo JA, Burnham WM, Head E, Cotman CW, Milgram NW (2006) Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia. Neurobiol Learn Mem 86, 197-204.
42. Head E, Mehta R, Hartley J, Kameka AM, Cummings BJ, Cotman CW, Ruehl WW, Milgram NW (1995) Spatial learning and memory as a function of age in the dog. Behav Neurosci 109, 851-858.
43. Robertson DG, Urda ER, Rothwell CE, Walsh KM (1997) Atorvastatin is not cataractogenic in beagle dogs. Curr Eye Res 16, 1229-1235.
44. Walsh KM, Albassam MA, Clarke DE (1996) Subchronic tox-icity of atorvastatin, a hydroxymethylgutaryl-coenzyme A re-ductase inhibitor, in beagle dogs. Toxicol Pathol 24, 468-476.
45. Milgram NW, Head E, Zicker SC, Ikeda-Douglas CJ, Murphey H, Muggenburg B, Siwak C, Tapp D, Cotman CW (2005) Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiol Aging 26, 77-90.
46. Head E, Callahan H, Muggenburg BA, Cotman CW, Milgram NW (1998) Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging 19, 415425.
47. Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H, 3rd, Keller JN (2007) Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 27, 301-311.
48. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/-knock-out mice. J Neurosci 23, 8532-8538.
49. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, Barrett E, Cribbs D (2008) A two-year study with fibrillar beta-amyloid βAbeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 28, 3555-3566.
50. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766.
51. Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H, Vassar R (2005) Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem 280, 18755-18770.
52. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G (2007) Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 282, 26832-26844.
53. Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C, Browne P (2006) Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 185, 78-86.
54. Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, Manuck SB (2000) Effects of lovastatin on cognitive function and psychological well-being. Am J Med 108, 538-546.
55. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB (2004) Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 117, 823-829.
56. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwol-ski C (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62, 753-757.
57. Franke C, Noldner M, Abdel-Kader R, Johnson-Anuna LN, Gibson Wood W, Muller WE, Eckert GP (2007) Bcl-2 up-regulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis 25, 438-445.
58. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C (2005) Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer Res 2, 343-353.
59. Cotman CW, Head E (2008) The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis 15, 685-707.
60. Locatelli S, Lutjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K (2002) Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 59, 213-216.
61. Vega GL, Weiner MF, Lipton AM, Von Bergmann K, Lutjo-hann D, Moore C, Svetlik D (2003) Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 60, 510-515.
62. Link JJ, Rohatgi A, de Lemos JA (2007) HDL cholesterol: physiology, pathophysiology, and management. Curr Probl Cardiol 32, 268-314.
63. Kakafika A, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP (2008) High density lipoprotein cholesterol and statin trials. Curr Med Chem 15, 2265-2270.
64. Li L, Cao D, Kim H, Lester R, Fukuchi K (2006) Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 60, 729-739.
65. Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolkowski C, Lochhead J, Browne P (2005) Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res 2, 527-539.
66. Stolley SN, Ito MK (1999) Lipophilic nature of atorvastatin. Am J Health Syst Pharm 56, 1988-1989.
67. Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12, 105-112.
68. Saito M, Benson EP, Rosenberg A (1987) Metabolism of cholesterol and triacylglycerol in cultured chick neuronal cells, glial cells, and fibroblasts: accumulation of esterified cholesterol in serum-free culture. J Neurosci Res 18, 319-325.
69. Chou YC, Lin SB, Tsai LH, Tsai HI, Lin CM (2003) Cholesterol deficiency increases the vulnerability of hippocampal glia in primary culture to glutamate-induced excitotoxicity. Neurochem Int 43, 197-209.
70. Tsai HI, Tsai LH, Chen MY, Chou YC (2006) Cholesterol deficiency perturbs actin signaling and glutamate homeostasis in hippocampal astrocytes. Brain Res 1104, 27-38.
71. Champagne D, Pearson D, Dea D, Rochford J and Poirier J (2003) The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: Implications for Alzheimer's Disease. Neuroscience 121, 99-110.
72. Cibickova L, Radomir H, Stanislav M, Norbert C, Helena Z, Daniel J, Alena T, Eva B, Vladimir P (2009) The influence of simvastatin, atorvastatin and high-cholesterol diet on acetyl-cholinesterase activity, amyloid beta and cholesterol synthesis in rat brain. Steroids 74, 13-19.
73. Simopoulos AP (2002) The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 56, 365-379.
74. Malhotra HS, Goa KL (2001) Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 61, 1835-1881.
75. Rubba P (2007) Effects of atorvastatin on the different phases of atherogenesis. Drugs 67(Suppl 1), 17-27.
76. Hartmann T (2006) Role of amyloid precursor protein, amyloid-beta and gamma-secretase in cholesterol maintenance. Neurodegener Dis 3, 305-311.
77. Sparks DL (2008) The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer's disease: the old, the new and the pilot. J Alzheimers Dis 15, 641-656.
78. Sparks DL, Scheff SW, Hunsaker JC, 3rd, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126, 88-94.
79. Ronald JA, Chen Y, Bernas L, Kitzler HH, Rogers KA, Hegele RA, Rutt BK (2009) Clinical field-strength MRI of amyloid plaques induced by low-level cholesterol feeding in rabbits. Brain 132, 1346-1354.
80. Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, Jung MW, Bang OY, Kim SU, Mook-Jung I (2003) Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 24, 637-643.
81. Hou Y, White RG, Bobik M, Marks JS, Russell MJ (1997) Distribution ofbeta-amyloid in the canine brain. NeuroReport 8, 1009-1012.
82. Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y (2008) Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clini-copathologic study. Arch Neurol 65, 906-912.
83. Murphy MP, LeVine H, 3rd (2010) Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 19, 311-323.
84. Roher A, Wolfe D, Palutke M, KuKuruga D (1986) Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci U S A 83, 2662-2666.
85. Ishii K, Tokuda T, Matsushima T, Miya F, Shoji S, Ikeda S, Tamaoka A (2003) Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans. Neurosci Lett 350, 161-164.
86. Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A, Vanmechelen E, Vanderstichele H, Lutjohann D, Blennow K (2005) The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 19, 256-265.
87. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB (2002) Treatment with simvastatin in normocholes-terolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52, 346-350.
88. Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K (2004) Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61, 333-337.
89. Bodovitz S, Klein WL (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271, 4436-4440.
90. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dot-ti CG (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167, 953-960.
91. Jaya Prasanthi RP, Schommer E, Thomasson S, Thompson A, Feist G, Ghribi O (2008) Regulation of beta-amyloid levels in the brain ofcholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech Ageing Dev 129, 649-655.
92. Parsons RB, Farrant JK, Price GC, Subramaniam D, Austen BM (2007) Regulation of the lipidation of beta-secretase by statins. Biochem Soc Trans 35, 577-582.
93. Wang CY, Liu PY, Liao JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14, 37-44.
94. Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45, 89-118.
95. Cole SL, Vassar R (2006) Isoprenoids and Alzheimer's disease: a complex relationship. Neurobiol Dis 22, 209-222.
96. Bazan NG (2009) Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 50 Suppl, S400-405.
97. Pappolla MA (2008) Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 71, 2020; author reply 2020-2021.